title: Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France.
abstract: We studied the propagation and the impact of zidovudine prevention on the human immunodeficiency virus-1 transmission rate from infected mothers to their infants in the French nationwide prospective cohort. Infection was diagnosed in the children on the basis of at least two positive human immunodeficiency virus-1 polymerase chain reaction tests, culture, or both. The transmission rate among treated women was compared with that among untreated women during the same period and with that among women enrolled in the cohort since 1986. The impact of zidovudine was analyzed according to the women's clinical and biologic characteristics, the mode of delivery, and use of zidovudine therapy before the pregnancy. Nearly 90% of women were treated as soon as the second half of 1994. In 1994 and 1995, 80% of mother-child pairs received at least one of the three phases of preventive treatment. Among the 663 mothers enrolled during these 2 years, only six refused the treatment. Zidovudine treatment was associated with a reduction in the transmission rate of nearly two-thirds, from 14% +/- 6% to 5% +/- 2% (p < 0.01). The degree of reduction was not influenced by the maternal CD4+ cell count or p24 antigenemia at delivery. Zidovudine treatment of the mother before the pregnancy considerably reduced the impact of preventive therapy; the transmission rate was significantly higher among pretreated mothers (20% versus 5%, p < 0.01) even after adjusting for maternal CD4+ cell count. Zidovudine prevention is now widely used in France and has had a major impact on the epidemiology of mother-child human immunodeficiency virus transmission. This justifies a policy of offering human immunodeficiency virus screening to all women before or shortly after the diagnosis of pregnancy.
authors.affiliation: Institut National de la Santé et la Recherche Médicale (INSERM) Unité 292 Hôpital Bicêtre, Le Kremlin Bicêtre, France.
authors.forename: M J
authors.initials: MJ
authors.lastname: Mayaux
authors.forename: J P
authors.initials: JP
authors.lastname: Teglas
authors.forename: L
authors.initials: L
authors.lastname: Mandelbrot
authors.forename: A
authors.initials: A
authors.lastname: Berrebi
authors.forename: H
authors.initials: H
authors.lastname: Gallais
authors.forename: S
authors.initials: S
authors.lastname: Matheron
authors.forename: N
authors.initials: N
authors.lastname: Ciraru-Vigneron
authors.forename: F
authors.initials: F
authors.lastname: Parnet-Mathieu
authors.forename: A
authors.initials: A
authors.lastname: Bongain
authors.forename: C
authors.initials: C
authors.lastname: Rouzioux
authors.forename: J F
authors.initials: JF
authors.lastname: Delfraissy
authors.forename: S
authors.initials: S
authors.lastname: Blanche
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology / Q000517:prevention & control*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D016001:Confidence Intervals; D005260:Female; D005602:France / Q000453:epidemiology; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D015999:Multivariate Analysis; D016017:Odds Ratio; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D018570:Risk Assessment; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine